Template for preparing submission using Overleaf

Author One

Author Two

Author Three

Author Four

# Introduction

Currently, metastatic breast cancer is difficult to treat. Patients with hormone receptor HR-positive and HER2-negative, the most common subtype, typically undergo endocrine therapy. Therefore, new treatments can be very useful in improving quality of life, reducing toxicity, and decreasing scenarios of hormonal resistance. Medications from the group of cyclin-dependent kinase inhibitors appear as a potential improvement in the therapeutic approach to advanced breast cancer. Within this group, there are palbociclib, ribociclib, and abemaciclib. Cyclin-dependent kinases 4 and 6 CDK4/6 are responsible for regulating the cell cycle at the transition between the G1 and S phases. In many neoplasms, this cycle is deregulated, and it promotes uncontrolled cell proliferation. It is then possible for these medications to have better effectiveness. These medications were approved by INFARMED, I.P. after an analysis of the therapeutic value they offer. For this purpose, data from clinical trials conducted with these medications were essentially used. The MONALEESA (Hortobagyi et al. 2018; Slamon et al. 2018; Tripathy et al. 2018) studies were used for ribociclib, PALOMA (Verma et al. 2016; Rugo et al. 2018; Finn et al. 2015) for palbociclib, and MONARCH (Goetz et al. 2017; Sledge et al. 2017) for abemaciclib. These studies focused on testing the hypothesis of treating CDK4/6 inhibitors in combination with an aromatase inhibitor or fulvestrant as an alternative to the gold standard. In these studies, it was concluded that they brought a significant increase in effectiveness, justifying their use in clinical practice. However, this evaluation was based on clinical trials with very specific inclusion and exclusion criteria and in a highly controlled environment. It is then vital to study how these new molecules compare to current practice in terms of treatment effectiveness in a real-world setting.

# Materials and Methods

## Study Design

This retrospective study was designed in 2022. The aim of the study was to evaluate the clinical benefit and long-term survival of patients with HR+/HER2 that started treatment with CDK46 inhibitors plus hormonotherapy in different lines of treatment between the 14th of March 2017 and the 31st of December 2021. The follow-up period was set until June 2022. Inclusion criteria: postmenopausal women, men, Oestrogen Receptor positive % (defined by ER expression 1 % of tumour cell by immunohistochemistry, IHC) and HER2 negative (by IHC and/or amplification assay) in the primary tumour or metastatic site after biopsy. Exclusion criteria: Patients that had only ambulatory medication, and patients involved in clinical trials, diagnosed with other neoplasms or with active treatment during the study period. The comparison group was defined by a population of patients, that were treated with hormone therapy as first-line (due to bone metastases) between 2015 and 13 of match 2017.

The evaluation of effectiveness will involve overall survival and progression-free analysis. We will compare the three different cyclin-dependent kinase inhibitors in terms of efficacy in real-world patients and will also compare the effectiveness of this class of drug against traditional hormonotherapy.

## Data collection

All data were collected from original medical records from baseline to last visit or death. The data was collected from Instituto Português de Oncologia – Porto (IPO-P). table [1](#tab:stats_ipop_cdk) shows a comparison between the groups. Data included for population treated with CDK46 inhibitors plus hormonotherapy: demographic information, age at first diagnosis and age at the beginning of treatment, clinical characteristics, and performance status by Eastern Cooperative Oncology Group scale (ECOG), treatment line and treatment schema - CDK46 inhibitor and hormonotherapy, stage of the cancer, site of metastases (bone, soft tissue, visceral, visceral and bone, central nervous system-CNS with or without another site). Data included for population treated with hormonotherapy as first-line: demographic information, age at first diagnosis and age at the beginning of treatment, clinical characteristics and performance status by Eastern Cooperative Oncology Group scale (ECOG), stage of the cancer.

For comparison purposes, we used palbociclib and ribociclib since we had a small number of patients treated with abemaciclib (12). We also filtered by 1st line to assess the best treatment option.

Descriptive statistics of cyclin-dependent kinase inhibitors group

|  | Palbociclib | Ribociclib | Overall |
| --- | --- | --- | --- |
|  | (N=247) | (N=106) | (N=353) |
|  |  |  |  |
| Mean (SD) | 59.2 (11.7) | 58.2 (10.7) | 58.9 (11.4) |
| Median [Min, Max] | 60.0 [28.0, 84.0] | 58.0 [32.0, 79.0] | 59.0 [28.0, 84.0] |
|  |  |  |  |
| Exemestane | 1 (0.4%) | 0 (0%) | 1 (0.3%) |
| Fulvestrant | 180 (72.9%) | 10 (9.4%) | 190 (53.8%) |
| Letrozol | 66 (26.7%) | 96 (90.6%) | 162 (45.9%) |
|  |  |  |  |
| 1st Line | 127 (51.4%) | 98 (92.5%) | 225 (63.7%) |
| 2nd+ Lines | 120 (48.6%) | 8 (7.5%) | 128 (36.3%) |
|  |  |  |  |
| No | 58 (23.5%) | 24 (22.6%) | 82 (23.2%) |
| Yes | 189 (76.5%) | 82 (77.4%) | 271 (76.8%) |
|  |  |  |  |
| I | 22 (8.9%) | 7 (6.6%) | 29 (8.2%) |
| II | 75 (30.4%) | 22 (20.8%) | 97 (27.5%) |
| III | 75 (30.4%) | 18 (17.0%) | 93 (26.3%) |
| IV | 65 (26.3%) | 46 (43.4%) | 111 (31.4%) |
| Missing | 10 (4.0%) | 13 (12.3%) | 23 (6.5%) |

Descriptive statistics of palbociclib and ribociclib (1st line) group vs hormonotherapy

|  | CDK4/6 | Chemo | Overall |
| --- | --- | --- | --- |
|  | (N=225) | (N=43) | (N=268) |
|  |  |  |  |
| Mean (SD) | 59.1 (11.5) | 60.1 (12.4) | 59.3 (11.6) |
| Median [Min, Max] | 59.0 [28.0, 84.0] | 62.0 [34.0, 85.0] | 60.0 [28.0, 85.0] |
|  |  |  |  |
| Palbociclib | 127 (56.4%) | 0 (0%) | 127 (47.4%) |
| Ribociclib | 98 (43.6%) | 0 (0%) | 98 (36.6%) |
| Anastrozol | 0 (0%) | 3 (7.0%) | 3 (1.1%) |
| Exemestano | 0 (0%) | 4 (9.3%) | 4 (1.5%) |
| Fulvestrant | 0 (0%) | 5 (11.6%) | 5 (1.9%) |
| Letrozol | 0 (0%) | 31 (72.1%) | 31 (11.6%) |
|  |  |  |  |
| + | 225 (100%) | 42 (97.7%) | 267 (99.6%) |
| - | 0 (0%) | 1 (2.3%) | 1 (0.4%) |
|  |  |  |  |
| + | 168 (74.7%) | 27 (62.8%) | 195 (72.8%) |
| - | 57 (25.3%) | 16 (37.2%) | 73 (27.2%) |
|  |  |  |  |
| I | 16 (7.1%) | 3 (7.0%) | 19 (7.1%) |
| II | 55 (24.4%) | 20 (46.5%) | 75 (28.0%) |
| III | 62 (27.6%) | 11 (25.6%) | 73 (27.2%) |
| IV | 75 (33.3%) | 2 (4.7%) | 77 (28.7%) |
| Missing | 17 (7.6%) | 7 (16.3%) | 24 (9.0%) |

## Statistical Analysis

R was used for statistical analysis. Demographic, clinical characteristics and side effects were analysed using descriptive statistics (count, percentages and median/range). Kaplan–Meier test was used to determine the median PFS and OS in the entire population and subgroups. Log-rank test was used for comparisons of PFS and OS among different subgroups. Cox Regression was used to assess feature importance and impact. All statistical tests were two-sided, and the significance level was 0.05.


# Results

Median OS in the entire population treated with CDK46 inhibitors was 46 months (95%CI 39.4–55.6). Median PFS was 20.3 months (95%CI 18.3–24.2). The median OS in the entire population after removing abemaciclib changed very little. When comparing Ribociclib and palbociclib with each other, we see that regarding OS, there is not significant difference, but ribociclib is significantly better in terms of PFS (p-value 0.001) (figure [1](#fig:interest)).


We then compared both with a cox-regression, checking that this trend continues where OS shows no significant difference between palbociclib and ribociclib but a significantly better PFS for ribociclib (figure [2](#fig:cox)). When adjusted to Stage, visceral metastases, Age and ECOG, ribociclib is associated to an HR of 0.44, implying that ribociclib as a first line treatment reduces the risk of the disease progression by 60% compared to palbociclib as first line treatment.

When comparing the traditional hormonotherapy with CDK4/6 inhibitors, we see that CDK4/6 inhibitors are significantly better in terms of PFS (p-value 0.001) but not OS. When comparing ribociclib first line, we see significant difference both in terms of PFS and OS (figure [3](#fig:grouped)).


When comparing palbociclib and ribociclib adjusted for propensity scores, we see that the trend continues, with no significant difference between the two in terms of OS but significant in terms of PFS (figure [4](#fig:propensity)). We matched for number of metastases, treatment line, combination drug, ECOG, age at beginning of treatment, bone metastases and visceral metastases.




Survival curves for Palbociclib and Ribociclib - Progression Free Survival and Overall Survival



Cox Regression with palbociclib and Ribociclib - Progression Free Survival and Overall Survival



Comparision of traditional hormonotherapy and CDK4/6 inhibitors



Comparison of palbociclib and ribociclib adjusted for propensity scores

# Discussion

The aim of this prospective study was to evaluate the real-world use of palbociclib and ribociclib in combination with ET for HR+/HER2 and comparing this drug class with traditional hormonotherapy. Few real-world evidence studies of palbociclib and ribociclib used in daily clinical practice have been published identifying clinical benefit, patient profile and sequencing of treatment, with even less evidence of use of palbociclib in Portugal.

When comparing with clinical trials, regarding patient profile, in our study, 51% had visceral metastasis and 35% bone only disease comparing with 49% and 38% in PALOMA-2, and 60% and 25% in PALOMA-3, respectively (Rugo et al. 2018; Cristofanilli et al. 2016). As for ribociclib, MONALEESA-7 (Tripathy et al. 2018) has 24% and MONALEESA-2 has 40% (Hortobagyi et al. 2018) and our study has 30%.

Of note, the range of median PFS for first-line palbociclib was plus letrozole in RWE studies was 15.5–25.5 months, which is shorter than 27.6 months observed in a post hoc analysis of the PALOMA-2 clinical trial with extended follow-up (Rugo et al. 2018), but in line with RWE studies (13.3–20.2 months) (Harbeck et al. 2021). As for ribo

# Conclusions

For conclusions and next steps, we feel we have demonstrated that the ribociclib is a good alternative to palbociclib. We still do not have sufficient evidence to state that palbociclib is actually better than traditional hormonotherapty regarding Overall Survival. However, it is sufficient to state that CDK4/6i have impact on PFS. Further information about the population could be interesting, as well as providing information about safety, economic impact and quality of life. We aim to address those issues in sequencing papers.

# Author contributions

…

# Institutional review

This work was approved by the ... Ethics Committee...

# Data availability

...

# Funding

…

# Acknowledgments

...

# Conflicts of interest

The authors declare no conflict of interest.

# Figure

# Table

# Supplementary Material

Cristofanilli, Massimo, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock-Ah Im, Norikazu Masuda, Marco Colleoni, et al. 2016. “Fulvestrant Plus Palbociclib Versus Fulvestrant Plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial.” *The Lancet. Oncology* 17 (4): 425–39. <https://doi.org/10.1016/S1470-2045(15)00613-0>.

Finn, Richard S, John P Crown, Istvan Lang, Katalin Boer, Igor M Bondarenko, Sergey O Kulyk, Johannes Ettl, et al. 2015. “The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study.” *The Lancet Oncology* 16 (1): 25–35. <https://doi.org/10.1016/S1470-2045(14)71159-3>.

Goetz, Matthew P., Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, et al. 2017. “MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 35 (32): 3638–46. <https://doi.org/10.1200/JCO.2017.75.6155>.

Harbeck, Nadia, Meaghan Bartlett, Dean Spurden, Becky Hooper, Lin Zhan, Emily Rosta, Chris Cameron, Debanjali Mitra, and Anna Zhou. 2021. “CDK4/6 Inhibitors in HR+/HER2- Advanced/Metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies.” *Future Oncology* 17 (16): 2107–22. <https://doi.org/10.2217/fon-2020-1264>.

Hortobagyi, G., S. Stemmer, H. Burris, Y. Yap, G. Sonke, S. Paluch-Shimon, M. Campone, et al. 2018. “Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer.” *Annals of Oncology : Official Journal of the European Society for Medical Oncology*. <https://doi.org/10.1093/annonc/mdy155>.

Rugo, H. S., V. Diéras, K. A. Gelmon, R. S. Finn, D. J. Slamon, M. Martin, P. Neven, et al. 2018. “Impact of Palbociclib Plus Letrozole on Patient-Reported Health-Related Quality of Life: Results from the PALOMA-2 Trial.” *Annals of Oncology: Official Journal of the European Society for Medical Oncology* 29 (4): 888–94. <https://doi.org/10.1093/annonc/mdy012>.

Slamon, Dennis J., Patrick Neven, Stephen Chia, Peter A. Fasching, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, et al. 2018. “Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 36 (24): 2465–72. <https://doi.org/10.1200/JCO.2018.78.9909>.

Sledge, George W., Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, et al. 2017. “MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.” *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* 35 (25): 2875–84. <https://doi.org/10.1200/JCO.2017.73.7585>.

Tripathy, Debu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, et al. 2018. “Ribociclib Plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor-Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial.” *The Lancet. Oncology* 19 (7): 904–15. <https://doi.org/10.1016/S1470-2045(18)30292-4>.

Verma, Sunil, Cynthia Huang Bartlett, Patrick Schnell, Angela M. DeMichele, Sherene Loi, Jungsil Ro, Marco Colleoni, et al. 2016. “Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).” *The Oncologist* 21 (10): 1165–75. <https://doi.org/10.1634/theoncologist.2016-0097>.